Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Global Stem Cell Technology

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              BELGIUM Belgium

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              BIO IMPACT

              Participation Not Confirmed

              Update your events

              Boehringer Ingelheim Acquires GST to Strengthen its Stem Cell Capabilities in Animal Health

              Contact the Supplier

              Lead Product(s): Mesenchymal stem cell therapy

              Therapeutic Area: Musculoskeletal Product Name: Arti-Cell

              Highest Development Status: Approved Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition July 27, 2020

              Details:

              The acquisition follows two years of successful partnership that brought the first-ever registered stem cell-based veterinary medicine to the European market.

              Mithra Pharmaceuticals

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              BELGIUM Belgium

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              BIO IMPACT

              Participation Not Confirmed

              Update your events

              Mithra Signs LSA for Commercialization of Tibelia® in Liechtenstein and Switzerland

              Contact the Supplier

              Lead Product(s): Tibolone

              Therapeutic Area: Musculoskeletal Product Name: Tibelia

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Spirig Healthcare

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement June 11, 2020

              Details:

              Developed by Mithra as the bioequivalent version of Livial® Tibelia® is a complex oral formulation composed of tibolone. Under the terms of this agreement, Spirig Healthcare AG will be responsible for the commercialization of Tibelia® in Liechtenstein and Switzerland.

              PharmaCompass__DigitalAd